Issue link: https://uberflip.scri.com/i/1521062
0529/24SCR019-14/R3 Abstract Presentation Calendar ASCO® 2024 5 Saturday Friday Sunday Monday Tuesday Publication Only SATURDAY, JUNE 1 ST 9:00am - 12:00pm Central Time (continued) Time Presentation Time Session Location Presentation Type Abstract Number Presentation Title 1st Author *SCRI First Author in Bold SCRI-Affiliated Coauthors Session Name 9:00am - 12:00pm Hall A Poster TPS3176 A first-in-human, phase 1 study evaluating oral TACC3 inhibitor, AO- 252, in advanced solid tumors. Dumbrava E Richardson D Developmental Therapeutics— Molecularly Targeted Agents and Tumor Biology 9:00am - 12:00pm Hall A Poster TPS2677 An open-label, phase 1, multicenter study to evaluate the safety and preliminary anti-tumor activity of NT-112 in human leukocyte antigen-C*08:02–positive adult patients with unresectable, advanced, and/or metastatic solid tumors that are positive for the KRAS G12D mutation. Punekar S Pelster M Developmental Therapeutics— Immunotherapy 9:00am - 12:00pm Hall A Poster TPS3169 Dose-expansion part of a phase 1b global study of E7386 in combination with lenvatinib (LEN) in patients (pts) with hepatocellular carcinoma (HCC) and other solid tumors including endometrial cancer (EC). Lee JY Ulahannan S Developmental Therapeutics— Molecularly Targeted Agents and Tumor Biology 9:00am - 12:00pm Hall A Poster TPS3164 HERTHENA-PanTumor01: A global, multicohort, phase 2 trial of HER3- DXd in relapsed/refractory metastatic solid tumors. Bhatia A McKean M Developmental Therapeutics— Molecularly Targeted Agents and Tumor Biology 9:00am - 12:00pm Hall A Poster TPS3175 A first-in-human, phase 1/2 trial of FOG-001, a β-catenin:TCF antagonist, in patients with locally advanced or metastatic solid tumors. Papadopoulos K Pelster M Developmental Therapeutics— Molecularly Targeted Agents and Tumor Biology 9:00am - 12:00pm Hall A Poster TPS2676 A phase 1/2, open-label, multicenter, dose escalation and cohort expansion study of the safety and efficacy of anti-CD70 allogeneic CRISPR-Cas9– engineered T cells (CTX131) in adult patients with relapsed or refractory solid tumors. Pal S Garmezy B Developmental Therapeutics— Immunotherapy 9:00am - 12:00pm Hall A Poster TPS2704 A phase 1/1b, first-in-human, multi-part study of DF6215, an engineered IL-2Rα-active agonist, to investigate the safety, tolerability, pharmacokinetics, and biological and clinical activity in patients with advanced solid tumors. Carneiro B McKean M Developmental Therapeutics— Immunotherapy 9:00am - 12:00pm Hall A Poster TPS3160 An open-label phase 1 study to investigate SGNCEACAM5C/ SAR445953 in adults with advanced solid tumors (SGNCEA5C-001). Patnaik A Pelster M, Perez C Developmental Therapeutics— Molecularly Targeted Agents and Tumor Biology 9:00am - 12:00pm Hall A Poster TPS3172 A phase 1 trial evaluating the safety, tolerability, PK, and preliminary efficacy of QTX3034, an oral G12D- preferring multi-KRAS inhibitor, in patients with solid tumors with KRASG12D mutation. Patnaik A Pelster M Developmental Therapeutics— Molecularly Targeted Agents and Tumor Biology